{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:14:13Z","timestamp":1792113253559,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ijcard.2021.01.061","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T22:37:28Z","timestamp":1612478248000},"page":"164-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Real-world effectiveness and safety of sacubitril\/valsartan in heart failure: A systematic review"],"prefix":"10.1016","volume":"331","author":[{"given":"Clare","family":"Proudfoot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Studer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvi","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramandeep","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumjhum","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Corda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2021.01.061_bb0005","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"27","key":"10.1016\/j.ijcard.2021.01.061_bb0010","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"issue":"13","key":"10.1016\/j.ijcard.2021.01.061_bb0015","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"Yancy","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.ijcard.2021.01.061_bb0020","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur. J. Heart Fail."},{"issue":"15","key":"10.1016\/j.ijcard.2021.01.061_bb0025","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.jacc.2019.08.001","article-title":"2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"74","author":"Hollenberg","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2021.01.061_bb0030","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11936-018-0638-7","article-title":"Sacubitril\/valsartan: from clinical trials to real-world experience","volume":"20","author":"Joly","year":"2018","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"issue":"3","key":"10.1016\/j.ijcard.2021.01.061_bb0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10557-019-06858-0","article-title":"Sacubitril\/valsartan in real-life practice: experience in patients with advanced heart failure and systematic review","volume":"33","author":"Moliner-Ab\u00f3s","year":"2019","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"11","key":"10.1016\/j.ijcard.2021.01.061_bb0040","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijcard.2021.01.061_bb0045","series-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses","author":"Wells","year":"2011"},{"key":"10.1016\/j.ijcard.2021.01.061_bb0050","author":"Core Team"},{"issue":"4","key":"10.1016\/j.ijcard.2021.01.061_bb0055","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jjcc.2019.03.010","article-title":"Sacubitril\/valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation","volume":"74","author":"Chang","year":"2019","journal-title":"J. Cardiol."},{"issue":"9","key":"10.1016\/j.ijcard.2021.01.061_bb0060","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011089","article-title":"Lower hospitalization and healthcare costs with sacubitril\/valsartan versus angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker in a retrospective analysis of patients with heart failure","volume":"8","author":"Albert","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"Suppl_1","key":"10.1016\/j.ijcard.2021.01.061_bb0065","article-title":"Hospitalization rates and costs among real world users of sacubitril\/valsartan versus other heart failure medications","volume":"138","author":"Parlett","year":"2018","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ijcard.2021.01.061_bb0070","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.cardfail.2019.07.167","article-title":"The use of sacubitril\/valsartan in an advanced heart failure clinic is associated with decreased heart failure hospitalizations, improved left ventricular ejection fraction and functional class","volume":"25","author":"Meloche","year":"2019","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.ijcard.2021.01.061_bb0075","first-page":"S59","article-title":"Reduction in hospitalization and medical costs among patients initiated with sacubitril\/valsartan: insights from an administrative database in the united states","volume":"23","author":"Albert","year":"2017","journal-title":"J. Manag. Care Special. Pharmacy"},{"issue":"10 A","key":"10.1016\/j.ijcard.2021.01.061_bb0080","article-title":"Hospitalization in patients with heart failure and reduced ejection fraction and diabetes treated with sacubitril\/valsartan versus angiotensin-converting enzyme inhibitor or angiotensin receptor blocker","volume":"24","author":"Chang","year":"2018","journal-title":"J. Manag. Care Special. Pharmacy"},{"issue":"5","key":"10.1016\/j.ijcard.2021.01.061_bb0085","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/00015385.2018.1521054","article-title":"Effects of sacubitril\/valsartan on functional status and exercise capacity in real-world patients","volume":"74","author":"Lau","year":"2018","journal-title":"Acta Cardiol."},{"issue":"1","key":"10.1016\/j.ijcard.2021.01.061_bb0090","first-page":"43","article-title":"Comparative effectiveness of sacubitril-valsartan versus ACE\/ARB therapy in heart failure with reduced ejection fraction","volume":"8","author":"Tan","year":"2020","journal-title":"JACC: Heart Fail."},{"issue":"11","key":"10.1016\/j.ijcard.2021.01.061_bb0095","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005691","article-title":"Characteristics and healthcare utilization among veterans treated for heart failure with reduced ejection fraction who switched to sacubitril\/valsartan","volume":"12","author":"Mohanty","year":"2019","journal-title":"Circ. Heart Fail."},{"issue":"11","key":"10.1016\/j.ijcard.2021.01.061_bb0100","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.cardfail.2019.11.003","article-title":"Clinical effectiveness of sacubitril\/valsartan among patients hospitalized for heart failure with reduced ejection fraction","volume":"25","author":"Greene","year":"2019","journal-title":"J. Card. Fail."},{"issue":"2","key":"10.1016\/j.ijcard.2021.01.061_bb0105","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/FJC.0000000000000641","article-title":"Sacubitril\/valsartan in daily clinical practice: data from a prospective registry","volume":"73","author":"Vicent","year":"2019","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"21 Supplement 1","key":"10.1016\/j.ijcard.2021.01.061_bb0110","first-page":"228","article-title":"editors. Prescription of sacubitril\/valsartan in a real-world population","author":"Joao Pedro Ribeiro Agostinho","year":"2019","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2021.01.061_bb0115","first-page":"97.2","article-title":"Mortality and hospitalization following initiation of sacubitril\/valsartan in the medicare population","volume":"3","author":"Roetker","year":"2019","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.ijcard.2021.01.061_bb0120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jjcc.2019.08.005","article-title":"Recovery of left ventricular dysfunction after sacubitril\/valsartan: predictors and management","volume":"75","author":"Chang","year":"2020","journal-title":"J. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcard.2021.01.061_bb0125","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ehf2.12258","article-title":"Insights into implementation of sacubitril\/valsartan into clinical practice","volume":"5","author":"Martens","year":"2018","journal-title":"ESC heart failure."},{"issue":"19 Supplement 1","key":"10.1016\/j.ijcard.2021.01.061_bb0130","first-page":"413","article-title":"editors. Results of a single center experience on 200 consecutive patients treated with Entresto (sacubitril\/valsartan)","author":"Canu","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"19 Supplement 1","key":"10.1016\/j.ijcard.2021.01.061_bb0135","first-page":"232","article-title":"editors. Tolerability and short-term outcomes of angiotensin receptor-neprilysin inhibitor (ARNI) use in a Singaporean cohort","author":"Koh","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"21 Supplement 1","key":"10.1016\/j.ijcard.2021.01.061_bb0140","first-page":"207","article-title":"editors. Real-world experience with angiotensin ii receptor blocker neprilysin inhibitor: reverse remodelling is the norm","author":"Ana Sofia Martinho","year":"2019","journal-title":"Eur. J. Heart Fail."},{"issue":"09","key":"10.1016\/j.ijcard.2021.01.061_bb0145","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2217\/cer-2019-0014","article-title":"Evolution of functional class, biochemical and echocardiographic parameters and clinical outcomes after sacubitril\/valsartan initiation in daily practice","volume":"8","author":"Morillas-Climent","year":"2019","journal-title":"J, Comp. Effect. Res."},{"issue":"3","key":"10.1016\/j.ijcard.2021.01.061_bb0150","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.hrthm.2017.11.012","article-title":"Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices","volume":"15","author":"de Diego","year":"2018","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.ijcard.2021.01.061_bb0155","article-title":"Angiotensin-neprilysin inhibition further reverses cardiac remodeling as compared to angiotensin inhibition in reduced heart failure patients","volume":"20","author":"De Diego","year":"2018","journal-title":"Europace"},{"issue":"20 (Suppl S1) 81","key":"10.1016\/j.ijcard.2021.01.061_bb0160","article-title":"editors. ARNI use leads to improved NYHA class and NT-proBNP levels in a Singaporean cohort","author":"Goh","year":"2018","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.ijcard.2021.01.061_bb0165","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ehf2.12547","article-title":"Sacubitril-valsartan in a routine community population: attention to volume status critical to achieving target dose","volume":"7","author":"Pharithi","year":"2020","journal-title":"ESC Heart Failure."},{"issue":"21 Supplement 1","key":"10.1016\/j.ijcard.2021.01.061_bb0170","first-page":"238","article-title":"editors. Use of sacubitril-valsartan in elderly patients. Subanalysis of the SAVE-RLife study","author":"Galvan Ruiz","year":"2019","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.ijcard.2021.01.061_bb0175","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/00325481.2018.1442090","article-title":"Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril\/valsartan in Germany","volume":"130","author":"Wachter","year":"2018","journal-title":"Postgrad. Med."},{"issue":"6","key":"10.1016\/j.ijcard.2021.01.061_bb0180","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s00059-018-4683-5","article-title":"Cognitive performance of patients with chronic heart failure on sacubitril\/valsartan","volume":"44","author":"De Vecchis","year":"2019","journal-title":"Herz"},{"issue":"11","key":"10.1016\/j.ijcard.2021.01.061_bb0185","first-page":"933","article-title":"Association between sacubitril\/valsartan initiation and health status outcomes in heart failure with reduced ejection fraction","volume":"7","author":"Khariton","year":"2019","journal-title":"JACC: Heart Failure."},{"key":"10.1016\/j.ijcard.2021.01.061_bb0190","article-title":"Tolerability and safety of Sacubitril\/Valsartan in real-life practice","volume":"20","author":"Joana Neiva","year":"2018","journal-title":"Eur. J. Heart Fail."},{"issue":"19 Supplement 1","key":"10.1016\/j.ijcard.2021.01.061_bb0195","first-page":"408","article-title":"editors. Use of sacubitril\/valsartan in a dedicated heart failure centre-real world experience from the first 110 patients","author":"Barrett","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"9 Supplement 1","key":"10.1016\/j.ijcard.2021.01.061_bb0200","article-title":"Translation of clinical trial to real world practice: can sacubitril-valsartan be safely titrated to target dose, 97\/103mg bi-daily, in clinical practice and what baseline characteristics predict successful titration?","volume":"73","author":"Dashwood","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"suppl_1","key":"10.1016\/j.ijcard.2021.01.061_bb0205","article-title":"The differential effects of valsartan\/sacubirtril on cardiac function in ischemic versus dilated cardiomyopathy: a 1 year real world study","volume":"136","author":"Pandey","year":"2017","journal-title":"Circulation"},{"issue":"20 Supplement 1","key":"10.1016\/j.ijcard.2021.01.061_bb0210","first-page":"412","article-title":"editors. Tolerance to the uptitration of the dose of sacubitril\/valsartan is comparable to that of angiotensin converting enzyme inhibitors; single center experience","author":"Elasfar","year":"2018","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"10.1016\/j.ijcard.2021.01.061_bb0215","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004302","article-title":"Adoption of sacubitril\/valsartan for the management of patients with heart failure","volume":"11","author":"Sangaralingham","year":"2018","journal-title":"Circ. Heart Fail."},{"issue":"16","key":"10.1016\/j.ijcard.2021.01.061_bb0220","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.ijcard.2021.01.061_bb0225","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro\u2013B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.ijcard.2021.01.061_bb0230","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","article-title":"Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF","volume":"38","author":"B\u00f6hm","year":"2017","journal-title":"Eur. Heart J."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527321001431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527321001431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:51:23Z","timestamp":1759092683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527321001431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":46,"alternative-id":["S0167527321001431"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2021.01.061","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness and safety of sacubitril\/valsartan in heart failure: A systematic review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2021.01.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}